Pain score as a predictor of subsequent fragility fracture in postmenopausal patients with rheumatoid arthritis: A retrospective case-control study

被引:0
|
作者
Yoshii, Ichiro [1 ]
Sawada, Naoya [2 ]
Chijiwa, Tatsumi [3 ]
机构
[1] Yoshii Clin, Dept Musculoskeletal Med, 6-7-5 Nakamura Ohashidori, Shimanto, Kochi 7870033, Japan
[2] Dohgo Onsen Hosp, Dept Rheumatol, Matsuyama, Japan
[3] Kochi Mem Hosp, Dept Rheumatol, Kochi, Japan
关键词
Bone fragility; Female; Fracture; Pain; Rheumatoid arthritis; RISK;
D O I
10.1016/j.afos.2023.12.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Bone fragility fracture (BFF) is a serious incident in treating rheumatoid arthritis (RA). We hypothesized that pain degree during treatment RA correlated with incident BFF and validated how pain affects incident BFF (inc-BFF). Methods Postmenopausal RA patients treated for at least 3 years were recruited. The primary endpoint was the development of inc-BFF. Follow-up began with the first bone mineral density measurement (baseline) and continued until the development of the first BFF or termination of the study. Clinical indicators at baseline, including pain score using a visual analog scale (PS-VAS), were analyzed statistically using Cox regression analysis, receiver operation characteristics (ROC), Kaplan-Meier survival curve analysis (K-M), and chi-square test. Results A total of 239 patients were recruited. Using a multivariate Cox regression analysis, the baseline's PS-VAS and prevalent BFF (pr-BFF) demonstrated significantly higher risk ratios. For ROC, pr-BFF and PS-VAS had significant cutoff index (COI) (positive, 21.0) and an area under-curve of 0.692 (P < 0.001) and 0.616 (P < 0.01), respectively. PS-VAS > COI had a 2.24-fold higher hazard ratio than PS-VAS <= COI using K-M. When these 2 conditions were combined, patients with pr-BFF-positive and PS-VAS-positive had a sensitivity of 42.3% and a specificity of 88.8% for the inc-BFF. PS-VAS > COI had no statistical significance in the subgroup without pr-BFF, whereas the existence of pr-BFF had a significantly higher risk ratio in the PS-VAS <= COI. Conclusions The PS-VAS during RA treatment is a good indicator for predicting the inc-BFF in postmenopausal RA patients with pr-BFF.
引用
收藏
页码:150 / 156
页数:7
相关论文
共 50 条
  • [1] High incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study
    Gomez-Vaquero, Carmen
    Hernandez, Jose Luis
    Olmos, Jose Manuel
    Cerda, Dacia
    Calleja, Cristina Hidalgo
    Lopez, Juan Antonio Martinez
    Arboleya, Luis
    Rey, Francisco Javier Aguilar del
    Pardo, Silvia Martinez
    Vilamajo, Inmaculada Ros
    Armangue, Xavier Suris
    Grados, Dolors
    Audera, Chesus Beltran
    Suero-Rosario, Evelyn
    Gracia, Inmaculada Gomez
    Chamizo, Asuncion Salmoral
    Martin-Esteve, Irene
    Florez, Helena
    Naranjo, Antonio
    Castaneda, Santos
    Bruno, Soledad Ojeda
    Carazo, Sara Garcia
    Garcia-Vadillo, Alberto
    Vives, Laura Lopez
    Martinez-Ferrert, Angels
    Panos, Helena Borrell
    Acin, Pilar Aguado
    Castellanos-Moreira, Raul
    Satorra, Pau
    Tebe, Cristian
    Guanabens, Nuria
    [J]. BONE, 2023, 168
  • [2] INCIDENCE OF CLINICAL FRAGILITY FRACTURES IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS. A MULTICENTRIC CASE-CONTROL STUDY
    Gomez Vaquero, C.
    Olmos, J. M.
    Hernandez, J. L.
    Cerda, D.
    Hidalgo, C.
    Martinez Lopez, J.
    Arboleya Rodriguez, L. M.
    Aguilar del Rey, J.
    Martinez Pardo, S.
    Ros, I.
    Suris, X.
    Grados Canovas, D.
    Beltran Audera, C.
    Suero-Rosario, E.
    Gomez Gracia, I.
    Salmoral, A.
    Martin-Esteve, I.
    Florez, H.
    Naranjo, A.
    Castaneda, S.
    Ojeda, S.
    Garcia Carazo, S.
    Garcia-Vadillo, A.
    Lopez Vives, L.
    Martinez-Ferrer, A.
    Panos, H. Borrell
    Aguado, P.
    Castellanos-Moreira, R.
    Tebe, C.
    Guanabens, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 199 - 199
  • [3] The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study
    Kim, Seong-Kyu
    Kim, Ji-Won
    Lee, Hwajeong
    Park, Sung-Hoon
    Choe, Jung-Yoon
    Kim, Boyoung
    [J]. MEDICINE, 2023, 102 (26) : E34219
  • [4] Rheumatoid arthritis and incident fracture in women: a case-control study
    Brennan, Sharon L.
    Toomey, Liesje
    Kotowicz, Mark A.
    Henry, Margaret J.
    Griffiths, Hedley
    Pasco, Julie A.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2014, 15
  • [5] STROKE AND RHEUMATOID ARTHRITIS: A RETROSPECTIVE, MATCHED CASE-CONTROL STUDY
    Mudd, P. D.
    Heycock, R. W.
    Hamilton, J.
    Kelly, C. A.
    Barer, D. H.
    [J]. RHEUMATOLOGY, 2004, 43 : 144 - 144
  • [6] Symptomatic femoral head necrosis in patients with rheumatoid arthritis: A retrospective case-control study
    Wei, Qijiao
    Yan, Qing
    Lin, Diantian
    Gao, Fei
    Lin, He
    Chen, Zhihan
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2022, 10 (06)
  • [7] THE PREDICTORS OF FRAGILITY FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY
    Sinha, R.
    Bukhari, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 215 - 216
  • [8] Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study
    Koh, JungHee
    Ju, Ji Hyeon
    Chung, Min Kyung
    Kim, Ji Hun
    Jung, Seung Min
    Lee, Ji Yeon
    Lee, Jennifer
    Kwok, Seung-Ki
    Park, Sung-Hwan
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [9] Cognitive Impairment in Rheumatoid Arthritis Patients: A Case-Control Study
    Alves, Beatriz Rizkallah
    Vitturi, Bruno Kusznir
    Coutinho Nascimento, Bruno Azeredo
    Carneiro De Campos, Felipe Sobolewski
    Torigoe, Dawton Yukito
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [10] Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study
    Yuji Kishimoto
    Yoshihiro Kato
    Manami Uemura
    Koji Kuranobu
    [J]. BMC Rheumatology, 6